๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A phase II study of human rDNA alpha-2 interferon in patients with low grade non-Hodgkin's lymphoma

โœ Scribed by J. Wagstaff; P. Loynds; D. Crowther

Publisher
Springer
Year
1986
Tongue
English
Weight
480 KB
Volume
18
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase II trial of bisantrene in patients
Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas
โœ Thomas P. Miller; Stephen E. Jones; David S. Alberts; Cindy Mackel ๐Ÿ“‚ Article ๐Ÿ“… 1984 ๐Ÿ› Springer US ๐ŸŒ English โš– 239 KB

Sixteen heavily pretreated patients with advanced intermediate and high-grade diffuse non-Hodgkin's lymphoma (NHL) were treated with 260 mg/M2 of bisantrene every three weeks. Thirty infusions of bisantrene were given without evidence of objective response. Pain in the infused arm, with or without s

A phase I toxicity study of human rDNA i
A phase I toxicity study of human rDNA interferon in patients with solid tumours
โœ J. Wagstaff; G. Chadwick; A. Howell; N. Thatcher; J. H. Scarffe; D. Crowther ๐Ÿ“‚ Article ๐Ÿ“… 1984 ๐Ÿ› Springer ๐ŸŒ English โš– 503 KB

This study was designed to evaluate the clinical tolerance to multiple IM injections of rDNA-produced human alpha-2 interferon (IFN) (Schering-Plough 30500) in patients with solid tumours. IFN was administered in escalating IM doses in separate groups of patients daily for 14 days and then twice wee

Complete regression of a suprasellar sec
Complete regression of a suprasellar secondary mass in a patient with low-grade non-Hodgkin's Lymphoma (NHL) Treated With 2-Chlorodeoxyadenosine (CDA)
โœ deCataldo, F.; Baudo, F.; Ottonelli, C.; Italia, C.; Valdagni, R. ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 278 KB ๐Ÿ‘ 2 views

lymph node involvement with rt ureter compression that required a stent insertion. Brain CT showed a suprasellar lesion involving the diencephalic and chiasmatic regions (Fig. ). The patient was treated with CdA (2 hr-infusion of 0.14 mg/kg die ร— 7 days) and Dexamethasone (0.3 mg/kg die ร— 4 days). T